Abstracts Archive - Page 49 of 2425 - ACR Meeting Abstracts

Abstract Number: 0649 • ACR Convergence 2024
Urinary Acetylated Albumin as a Biomarker of Nephritis in Patients with Systemic Lupus Erythematosus
Yeo-Jin Lee¹, Eun-Ju Lee², Minji Kim³, Mi-Ra Cho⁴, Soo Min Ahn³, Seokchan Hong⁴, Ji Seon Oh⁴, Chang-Keun Lee⁴, Bin Yoo⁴ and Yong-Gil Kim³, ¹Asan medical center, Seoul, South Korea, ²Asan Institute for Life Sciences, Asan Medical Center, Seoul, Republic of Korea, ³Asan medical center, University of Ulsan College of Medicine, Seoul, Republic of Korea, ⁴Asan Medical Center, Seoul, Republic of Korea
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that affects multi-organ systems, particularly the kidneys. Urine is an ideal source of SLE biomarkers…
Abstract Number: 0641 • ACR Convergence 2024
Predictive Validity of Coronary Artery Calcium Scoring in Low Risk Systemic Lupus Erythematous Patients
Katherine Chakrabarti¹, Apurba Chakrabarti², Emily Lewis² and William McCune³, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan Hospital, Ann Arbor, MI, ³U Michigan, Ann Arbor, MI
Background/Purpose: Traditionally, a coronary artery calcium (CAC) score of zero is associated with low rates (0.1-0.2% annualized risk) of major adverse cardiovascular outcomes (MACE). While…
Abstract Number: 0698 • ACR Convergence 2024
Association of Systemic Sclerosis with ANCA-Associated Vasculitis and Large Vessel Vasculitis: Impact of Pulmonary Arterial Hypertension
Brett Dinner¹, Ahmed Abdelmaksoud², Ann Igoe³, Taylor Viggiano⁴ and Vivek Nagaraja⁵, ¹Creighton University, Paradise Valley, AZ, ²University of California, Riverside, Riverside, CA, ³Flow, Tempe, AZ, ⁴Mayo Clinic, Phoenix, ⁵Mayo Clinic Arizona, Scottsdale, AZ
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disorder with excessive fibrosis and vasculopathy. While typically non-inflammatory, frank vasculitis can complicate SSc. Concomitant SSc with ANCA-associated…
Abstract Number: 0711 • ACR Convergence 2024
Molecular Signatures in the Skin as Predictors of Longitudinal Clinical Trajectories in Patients with Systemic Sclerosis
Natania Field¹, Monica Yang², Niket Gupta¹, Maxwell Shramuk¹, Lutfiyya Muhammad¹, Vivien Goh¹, Monica Espinoza³, Yiwei Yuan³, Rezvan Parvizi³, Kathleen Aren⁴, Mary Carns⁴, Isaac Goldberg⁵, Lorinda Chung⁶, Dinesh Khanna⁷, Zsuzsanna McMahan⁸, Michael Whitfield³ and Monique Hinchcliff⁹, ¹Northwestern Feinberg School of Medicine, Chicago, IL, ²UCSF, San Francisco, CA, ³Geisel School of Medicine at Dartmouth, Hanover, NH, ⁴Northwestern University Division of Rheumatology, Chicago, IL, ⁵Wayne State University School of Medicine, Detroit, MI, ⁶Stanford University, Woodside, CA, ⁷University of Michigan, Ann Arbor, MI, ⁸UTHealth Houston Division of Rheumatology, Houston, TX, ⁹Yale School of Medicine, Westport, CT
Background/Purpose: It has become clear that classification by phenotype is insufficient to explain the heterogeneity in clinical progression for many rheumatic diseases. Systemic sclerosis (SSc)…
Abstract Number: 0595 • ACR Convergence 2024
bDMARD Drug Survival in Combination Therapy with Methotrexate in Psoriatic Arthritis: A Systematic Literature Review and Meta-analysis
Sélina HANNA ABDELMASSIH¹, Tiphaine DUJARDIN², Athan BAILLET¹, Philippe GAUDIN¹ and Xavier ROMAND¹, ¹Centre hospitalier universitaire Grenoble-Alpes, Grenoble, France, ²Hôpital Reine Hortense, Aix-les-Bains, France
Background/Purpose: During the last two decades we’ve witnessed the rising use of biologic disease-modifying antirheumatic drugs (bDMARDs) in the treatment of psoriatic arthritis (PsA), leaving…
Abstract Number: 0673 • ACR Convergence 2024
BCMA-CD19 Compound CAR-T (cCAR) Safely Provides a Complete Humoral Reset Eliminating All Autoantibodies Resulting in Long-term Medication-Free Complete Remission Among Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) Patients
Yong Yuan¹, Shanzhi He², Wenli Zhang³, Hongyu Zhang⁴, Vincent M DeStefano⁵, Masayuki Wada⁵, Kevin Pinz⁵, Greg Deener⁵, Yu Ma⁶, Min Wang², Fugui Li⁷, Ming Hong¹, Chanjuan Zou², Mingxia Wang², Ling Ding², Yingwen Liang⁸, Yupo Ma⁵ and Weija Wang⁹, ¹Department of Translational Medicine, Zhongshan people's Hospital, Zhongshan, China (People's Republic), ²Department of Rheumatoid Immunology, Zhongshan people's Hospital, Zhongshan, China (People's Republic), ³Department of Hematology, Peking University Shenzhen Hosptial, Shenzhen, China (People's Republic), ⁴Department of Hematology, Peking University Shenzhen Hospital, Shenzhen, China (People's Republic), ⁵iCell Gene Therapeutics, Inc., Stony Brook, NY, ⁶iCAR Bio Therapeutics Ltd, Zhongshan, China (People's Republic), ⁷Department of Translational Medicine. Zhongshan people's Hospital, Zhongshan, China (People's Republic), ⁸Department of Translational Medicine, Zhongshan's people Hospital, Zhongshan, China (People's Republic), ⁹Department of Translational Research, Zhongshan people's Hospital, Zhongshan, China (People's Republic)
Background/Purpose: Medication free complete remission (CR) has been elusive in SLE. An open label investigator-initiated trial (IIT) infused SLE/LN patients with a novel cCAR targeting…
Abstract Number: 0495 • ACR Convergence 2024
Correlation Between Triglyceride/Glucose Index and Functional Capacity in Rheumatoid Arthritis Patients
Yelitza Cecilia Velarde Mejia¹, Manuel Ugarte-Gil², Risto Perich³, Cesar Pastor⁴, Graciela Alarcon⁵ and RV, Gamboa-Cardenas⁶, ¹Hncase, Arequipa, Peru, ²Universidad Cientifica del Sur, Lima, Lima, Peru, ³Hospital Almenara, Lima, Peru, ⁴UNMSM, LIMA, Peru, ⁵The University of Alabama at Birmingham, Oakland, CA, ⁶Universidad Científica del Sur, Lima, Lima, Peru
Background/Purpose: The triglyceride/glucose index (TGI) is a metabolic marker associated with insulin resistance and cardiovascular risk. In patients with Rheumatoid Arthritis (RA), chronic inflammation and…
Abstract Number: 0511 • ACR Convergence 2024
Do High Rheumatoid Factor Levels Impact Response to Certolizumab Pegol in Patients with Inadequately Controlled Rheumatoid Arthritis? A Post Hoc Analysis of a Phase 3b Trial
Josef Smolen¹, Ted Mikuls², James Galloway³, Ulf Müller-Ladner⁴, Jeffrey Curtis⁵, Motomu Hashimoto⁶, Tsutomu Takeuchi⁷, Ernest Choy⁸, Yoshiya Tanaka⁹, Carlos Cara¹⁰, Bernard Lauwerys¹¹, Nicola Tilt¹², Baran Ufuktepe¹³ and Peter C. Taylor¹⁴, ¹Medical University of Vienna, Vienna, Austria, ²University of Nebraska Medical Center, Omaha, NE, ³Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ⁴Justus-Liebig University Giessen, Bad Nauheim, Germany, ⁵University of Alabama at Birmingham, Hoover, AL, ⁶Osaka Metropolitan University, Osaka, Japan, ⁷Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, ⁸Cardiff University School of Medicine, Cardiff, United Kingdom, ⁹Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ¹⁰UCB Pharma, Madrid, Spain, ¹¹UCB Pharma, Brussels, Belgium, ¹²UCB Pharma, Slough, United Kingdom, ¹³UCB Pharma, Istanbul, Turkey, ¹⁴University of Oxford, Oxford, United Kingdom
Background/Purpose: In pts with RA, high RF levels are associated with poor prognosis, higher disease activity, and decreased response to monoclonal antibodies targeting tumor necrosis…
Abstract Number: 0712 • ACR Convergence 2024
Efficacy of Sacubitril/Valsartan in Patients with Systemic Sclerosis and Heart Failure: A Retrospective Analysis
Nouran Eshak¹, Mahmoud Abdelnabi², Jaxon Quillen¹, Michael Pham¹, Joseph Hentz¹ and Vivek Nagaraja¹, ¹Mayo Clinic Arizona, Scottsdale, AZ, ²Mayo Clinic Arizona, Phoenix, AZ
Background/Purpose: Cardiac involvement in systemic sclerosis (SSc) is common, underdiagnosed, and manifests variably. Myocardial involvement can manifest as left heart failure with preserved or reduced…
Abstract Number: 0704 • ACR Convergence 2024
Progression of Global Longitudinal Strain and Identification of Left Ventricular Dysfunction in Systemic Sclerosis Patients
Jennifer Abdalla¹, Yuichiro Okushi², Chao Zhang³, Zoran Popovic², Heba Wassif¹ and Soumya Chatterjee⁴, ¹Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic, Cleveland, ³Cleveland Clinic, Cleveland Heights, OH, ⁴Cleveland Clinic, Richmond Heights, OH
Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune disease known for its fibrotic and vascular complications impacting various organs, including the heart. Myocardial involvement causes…
Abstract Number: 0026 • ACR Convergence 2024
Conserved Pro-Fibrotic Fibroblast Signatures in Osteoarthritis Synovium and Systemic Sclerosis Skin
Michael Newton¹, Aanya Mohan², Tareq Hanna³, Dana Orange⁴, John Varga² and Tristan Maerz², ¹University of Michigan, South Lyon, MI, ²University of Michigan, Ann Arbor, MI, ³Wayne State University, Detroit, MI, ⁴The Rockefeller University, New York, NY
Background/Purpose: Synovial fibrosis is a hallmark of osteoarthritis (OA) and a clinical correlate to joint pain. Fibrosis of skin, lungs and other organs is the…
Abstract Number: 0687 • ACR Convergence 2024
Patterns of Disease Progression in Early Systemic Sclerosis Patients with Interstitial Lung Disease
Lorenzo Beretta¹, Alessandro Santaniello², Silvia Bosello³, Enrico De Lorenzis⁴, Gerlando Natalello⁵, Nicoletta Del Papa⁶, Silvia Cavalli⁷, Devis Benfaremo⁸, Giacomo De Luca⁹, Corrado Campochiaro¹⁰, Lorenzo Cavagna¹¹, Veronica Codullo¹², Francesco Bonomi¹³, gaia Montanelli¹⁴, Adriana Severino¹⁵, Monica Caronni², Barbara Vigone², Silvia Bellando-Randone¹⁶, Carlomaurizio Montecucco¹⁷, Marco Matucci-Cerinic¹⁸, Lorenzo Dagna¹⁹, Gianluca Moroncini⁸, Roberto Caporali²⁰ and Chiara Bellocchi²¹, ¹Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di MIlano, Milan, Milan, Italy, ²Fondazione IRCCS Ca' Granda Ospedale Policlinico di Milano, MILANO, Italy, ³FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI- IRCCS, Rome, Rome, Italy, ⁴Catholic University of the Sacred Heart, Roma, Rome, Italy, ⁵Division of Rheumatology - Catholic University of the Sacred Heart, Fondazione Policlinico Universitario Agostino Gemelli, Rome, Rome, Italy, ⁶ASST Centro Specialistico Ortopedico Traumatologico Gaetano Pini-CTO, Milano, Milan, Italy, ⁷University of Milan, Milan, Milan, Italy, ⁸Marche Polytechnic University, Ancona, Italy, ⁹Vita-Salute San Raffaele University & IRCCS San Raffaele Hospital, Milan, Milan, Italy, ¹⁰IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, ¹¹University of Pavia and Fondazione IRCCS Policlinico San Matteo Hospital of Pavia, Pavia, Pavia, Italy, ¹²Division of Rheumatology - Policlinico San Matteo, Pavia, Italy, Pavia, Lombardia, Italy, ¹³Azienda Ospedaliera Universitaria Careggi, Florence, Florence, Italy, ¹⁴Fondazione IRCCS Ca' Granda Ospedale Policlinico di Milano, Milan, Italy, ¹⁵Fondazione IRCCS Ca' Granda Ospedale Policlinico di Milano, Milan, Milan, Italy, ¹⁶University of Florence, Florence, Florence, Italy, ¹⁷IRCCS policlinico S. Matteo foundation, University of Pavia, Pavia, Italy, ¹⁸University San Raffaele Milano, Milano, Milan, Italy, ¹⁹Ospedale San Raffaele, Milano, Italy, ²⁰Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milan, Italy, ²¹Università degli Studi di Milano, IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy
Background/Purpose: Understanding the trajectory of disease progression in SSc-ILD is crucial for effective patient management and prognostication. Trajectory modeling offers a novel approach to deciphering…
Abstract Number: 0678 • ACR Convergence 2024
Patients with Interstitial Lung Disease Due to Systemic Sclerosis or Rheumatoid Arthritis Need Monitoring More Frequently Than Annually
Oliver Distler¹, Margarida Alves², Gerrit Toenges³ and Anna-Maria Hoffmann-Vold⁴, ¹Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland, Zurich, Switzerland, ²Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, Ingelheim, Germany, ³Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany, Ingelheim am Rhein, Germany, ⁴Oslo University Hospital, Oslo, Norway
Background/Purpose: There is no consensus on the frequency of monitoring of patients with autoimmune disease-related interstitial lung diseases (ILDs), but a frequency of 1 year…
Abstract Number: 0691 • ACR Convergence 2024
Predictors of Response and Long-term Efficacy and Safety of Nintedanib in Systemic Sclerosis-Interstitial Lung Disease: Data from an Italian Multicentre Study
Corrado Campochiaro¹, Giacomo De Luca², Maria-Grazia Lazzaroni³, Giuseppe Armentaro⁴, Amelia Spinella⁵, Chiara Bellocchi⁶, Barbara Ruaro⁷, Anna Stanziola⁸, Devis Benfaremo⁹, Enrico De Lorenzis¹⁰, Beatrice Moccaldi¹¹, Francesco Bonomi¹², Lorenzo Bianchessi¹³, Florenzo Iannone¹⁴, Fabio Cacciapaglia¹⁵, Lorenzo Beretta¹⁶, Serena Guiducci¹⁷, Veronica Codullo¹⁸, Silvia Laura Bosello¹⁹, Giovanna Cuomo²⁰, Elisabetta Zanatta¹¹, Nicoletta Del Papa⁴, Paolo Airò³, paola Confalonieri⁷, Gianluca Moroncini⁹, Dilia Giuggioli⁵, Lorenzo Dagna²¹ and Marco Matucci-Cerinic²², ¹IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, ²Vita-Salute San Raffaele University & IRCCS San Raffaele Hospital, Milan, Milan, Italy, ³Scleroderma Unit, Rheumatology and Clinical Immunology Unit, ERN ReCONNET, ASST Spedali Civili, Brescia, Italy, Brescia, Italy, ⁴Scleroderma Clinic, Dip. Reumatologia, ASST G. Pini-CTO, Milan, Italy, ⁵Scleroderma Unit, University of Modena and Reggio Emilia, Modena, Italy, ⁶Università degli Studi di Milano, IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy, ⁷Unit of Respiratory Medicine, University of Trieste, Trieste, Italy, ⁸Unit of Respiratory Medicine, Federico II University Hospital, Napoli, Italy, ⁹Department of Clinical and Molecular Sciences, Marche Polytechnic University & Department of Internal Medicine, Marche University Hospital, Ancona, Italy, ¹⁰Catholic University of the Sacred Heart, Roma, Rome, Italy, ¹¹Unit of Rheumatology, Padova University, Padova, Italy, ¹²Azienda Ospedaliera Universitaria Careggi, Florence, Florence, Italy, ¹³Unit of Rheumatology, San Matteo Hospital, Pavia, ¹⁴Rheumatology Unit- University of Bari "Aldo Moro", IT, Bari, Italy, ¹⁵Rheumatology Unit � DiMePRe-J, University and AOU Policlinico of Bari, Italy, Bari, Italy, ¹⁶Scleroderma Unit, Fondazione IRCCS Ca' Granda, University of Milan, Milan, Italy, ¹⁷Division of Rheumatology, Scleroderma Unit, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ¹⁸Unit of Rheumatology, San Matteo Hospital, Pavia, Italy, ¹⁹Unit of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, ²⁰Università degli studi della Campania Luigi Vanvitelli, Napoli, Italy, ²¹IRCCS San Raffaele Scientific Institute, Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), Milano, Italy, Milan, Italy, ²²University San Raffaele Milano, Milano, Milan, Italy
Background/Purpose: The SENSCIS trial and the SENSCIS-ON study have shown that nintedanib (NTD) reduces the rate of decline in Interstitial Lung Disease (ILD) in Systemic…
Abstract Number: 0681 • ACR Convergence 2024
Influence of Occupational Exposure to Pollutants on Clinical and Serological Phenotypes in Systemic Sclerosis
Martina Sanahuja i Sanz¹, Irene Carrión-Barberà², Laura Tío³, Laura Triginer³, María Lee³, Alfredo Guillén-del Castillo⁴, Anna Ribes³, Lidia Valencia Muntalà⁵, Jordi Monfort², Tarek Carlos Salman Monte:⁶, Javier Narvaez-García⁷, Carmen PIlar Simeón-Aznar⁴ and Anna Pros², ¹Universitat Pompeu Fabra, Barcelona, Spain, ²Hospital del Mar, Barcelona, Spain, ³Hospital del Mar Research Institute, Barcelona, Spain, ⁴Hospital Vall d'Hebron, Barcelona, Spain, ⁵Hospital de Bellvitge, Barcelona, Spain, ⁶Hospital del Mar/Parc de Salut Mar-IMIM, Barcelona, Spain, ⁷Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: Environmental factors have been proposed as a trigger for systemic sclerosis (SSc) in genetically predisposed individuals. This study aimed to investigate the association between…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].